P003 Predictors of differential treatment response between adalimumab and methotrexate in psoriasis: a causal forest analysis of the British Association of Dermatologists Biologics and Immunomodulators Register

阿达木单抗 甲氨蝶呤 医学 银屑病 语域(社会语言学) 联想(心理学) 皮肤病科 内科学 疾病 心理学 语言学 哲学 心理治疗师
作者
Wei Yann Haw,Oras Alabas,Matthew Sperrin,Giovanni Ciná,Ameen Abu‐Hanna,Richard B. Warren
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:193 (Supplement_1)
标识
DOI:10.1093/bjd/ljaf085.031
摘要

Abstract While conventional comparative effectiveness studies report average treatment effects (ATEs), they may not capture the complex patterns of individual treatment responses. Causal forest, a tree-based machine learning approach that identifies patient-level factors influencing differential treatment responses, facilitates the estimation of conditional average treatment effects (CATEs) based on an individual’s covariates. Our aim was to identify patient characteristics that predict differential responses to adalimumab vs. methotrexate in psoriasis using causal forest analysis, and to characterize heterogeneous treatment effects across clinically relevant subgroups. The analysis compared biologic-naive adult patients who initiated either adalimumab or methotrexate between September 2007 and April 2024 across the UK and Republic of Ireland following the protocol recorded by the prospective registry the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Missing data were handled using one randomly selected dataset from multiple imputation by chained equations. A causal forest model was employed to estimate CATE for achieving Psoriasis Area and Severity Index (PASI) ≤ 2 during the treatment period, incorporating baseline patient characteristics and comorbidities. Variable importance analysis was used to identify key predictors of differential treatment response between adalimumab and methotrexate, with their effects quantified through best linear projection. In total 6810 patients (adalimumab 3974, methotrexate 2836) were included in the analysis. While adalimumab demonstrated superior overall effectiveness [ATE 0.41, 95% confidence interval (CI) 0.38–0.44], CATE analysis revealed substantial variation in individual treatment effects (median 0.42, interquartile range 0.37–0.47). Key predictors of differential treatment effects included male sex (absolute risk difference 0.15, P < 0.001). Effects were greater with increasing baseline PASI (0.007 per unit, P = 0.001), but lower with increasing age (−0.004 per year, P = 0.006) and weight (−0.003 per kg, P = 0.002). Subgroup analysis (CATE with 94% CI) showed higher treatment effects in younger patients (< 30 years: 0.46, 0.41–0.51 vs. > 70 years: 0.36, 0.34–0.39), female patients (0.45, 0.41–0.50 vs. male: 0.38, 0.35–0.41) and those with higher baseline PASI (> 20: 0.45, 0.41–0.49 vs. < 10: 0.41, 0.37–0.46). Increasing weight (< 90 kg: 0.43, 0.38–0.48 vs. > 120 kg: 0.40, 0.36–0.45) and comorbidity burden (no comorbidities: 0.44, 0.40–0.49 vs. ≥ 3 comorbidities: 0.37, 0.33–0.40) were associated with reduced treatment effects. The causal forest analysis reveals significant heterogeneity in responses to adalimumab and methotrexate, underscoring the impact of individual characteristics on treatment effectiveness. Factors such as age, sex, baseline PASI, weight and number of comorbidities are associated with differential treatment responses when prescribing adalimumab or methotrexate. These findings provide a data-driven framework to support personalized treatment decisions in clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tina完成签到,获得积分10
2秒前
llli完成签到,获得积分10
2秒前
meta完成签到,获得积分10
7秒前
认真的可冥完成签到,获得积分10
7秒前
SnlyEng完成签到 ,获得积分10
16秒前
文文完成签到 ,获得积分10
17秒前
神也慕我谦姝完成签到,获得积分10
20秒前
钟原完成签到 ,获得积分10
23秒前
lzy完成签到 ,获得积分10
24秒前
30秒前
31秒前
2滴水完成签到,获得积分10
32秒前
Lee发布了新的文献求助10
33秒前
小静完成签到 ,获得积分10
35秒前
好好好发布了新的文献求助10
36秒前
周小篆完成签到,获得积分10
36秒前
Clover04的应助被科研通管家采纳,获得20
36秒前
Clover04的应助被科研通管家采纳,获得10
37秒前
Maestro_S的应助被科研通管家采纳,获得10
37秒前
胖胖橘完成签到 ,获得积分10
37秒前
cdercder的应助被科研通管家采纳,获得10
37秒前
亓雅丽完成签到 ,获得积分10
37秒前
38秒前
yk完成签到,获得积分10
45秒前
蒜蒜完成签到 ,获得积分10
46秒前
朱科源啊源完成签到 ,获得积分0
48秒前
香蕉觅云的应助被Cell采纳,获得10
51秒前
积极凌兰完成签到 ,获得积分10
53秒前
大气钥匙完成签到,获得积分10
59秒前
YHBBZ完成签到 ,获得积分10
1分钟前
爱我不上火完成签到 ,获得积分10
1分钟前
天宇完成签到,获得积分10
1分钟前
vviruz完成签到,获得积分10
1分钟前
1分钟前
欧阳完成签到 ,获得积分10
1分钟前
Cell发布了新的文献求助10
1分钟前
两土日青发布了新的文献求助10
1分钟前
彭于晏的应助被好好好采纳,获得10
1分钟前
2026成功上岸完成签到 ,获得积分10
1分钟前
xia完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577468
关于积分的说明 21852573
捐赠科研通 7789024
什么是DOI,文献DOI怎么找? 3436347
关于科研通互助平台的介绍 2560154
邀请新用户注册赠送积分活动 2482995